Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 3.50 Billion |
| USD 5.37 Billion | |
| % | |
|
Global Pericarditis Drugs Market, By Drugs (Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Steroids, Antibiotics, Colchicine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The pericarditis drugs market is expected to witness significant growth during the forecast period. Rising prevalence of cardiovascular diseases worldwide and the growing markets are the factors responsible for expanding this market. The growth of global pericarditis drugs market enhanced by the growing cases of autoimmune diseases and the rise in R&D activities conducted by many pharmaceutical companies. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global pericarditis drugs market in the forecast period 2022-2029. The expected CAGR of global pericarditis drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 3.5 billion in 2021, and it would grow upto USD 5.37 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Pericarditis is the inflammation due to irritation & swelling of any layer of pericardium which surrounds the heart and consists of visceral pericardium, middle fluid layer, and parietal pericardium. The symptoms of pericarditis include chest pain, low grade fever and increased heart rate. Sharp chest pain associated with the pericarditis occurs when the irritated layers of the pericardium rub against each other. Pericarditis generally begins suddenly but isn't long lasting but when the symptoms develop gradually or persist, it may be chronic.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Steroids, Antibiotics, Colchicine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie Inc. (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India)
|
|
Market Opportunities
|
|
Drivers
Rise in prevalence of cardiovascular diseases and pericarditis is expected to drive the demand for pericarditis drugs. Cardiovascular diseases account for approximately 17.9 million deaths globally each year, with an estimated mortality rate of 31%. Over 75% of these deaths are witnessed in low- and middle-income countries. Thus, it boosts the market growth.
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
Adopting dual therapy for treating pericarditis patients is one of the driving factors for the global pericarditis drugs market. In old times, aspirin was used as monotherapy to treat acute pericarditis. Although, with each passing decade, clinical trials are being carried out for dual therapy combining aspirin with colchicine for the treatment of pericarditis. Its been witnessed that combination therapy is effective in decreasing the relapse rate of pericarditis than conventional monotherapy.
The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
The side effects associated with these pericarditis drugs could curb the growth of the global pericarditis drugs market over a forecast period. Effects such as racing heartbeat, leg swelling, fatigue, anxiety, fever can hamper the market growth.
The huge expenditure associated with these agents surely hamper the market growth.
This pericarditis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pericarditis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
Pericarditis witnessed to be widespread during the pandemic but was rarely seen in the post-acute period, on the other hand minor pericardial effusions seem to be very common during the COVID-19 post-acute period. Additionally, post-COVID pericarditis is found to be linked to continuing inflammation. Thus, COVID-19 had a major impact on the pericarditis drugs market.
The pericarditis drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
Route of Administration
End User
Distribution Channel
The pericarditis drugs market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the pericarditis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for global pericarditis drugs market due to high prevalence of cardiac surgeries & continuous rise in patients with cardiovascular diseases and rapidly improving health care infrastructure in the region.
North America dominates the market due to large number of patients diagnosed with heart diseases and high R&D and healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The pericarditis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pericarditis drugs market.
Key players operating in the pericarditis drugs market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.